|
Welcome to BiotechDueDiligence !
Follow on Twitter @BioDueDiligence Follow on Stocktwits @BioDueDiligence Use the search box below to quickly search the siteWhat is this site all about? Biotechnology is a fascinating stock market sector that most individual investors are both intrigued by and deathly afraid of. We all want to invest in the company developing the next blockbuster drug--but how can we avoid the next clinical trial or regulatory disaster that send shares down 80%? The key to success is, like most things, doing your homework. Gathering and assessing the critical information is the key to anticipating both positive and negative catalysts and reacting accordingly. BiotechDueDiligence is a free source for In-depth information on select small- and mid-cap biotechnology/pharmaceutical companies. If you are looking for more detailed, valued-added notes and analysis, please read more about subscribing to Chimera Research Group. Please read the full Disclaimer below, and understand that this site does not recommend that any individual or fund buy or sell a particular stock. What stocks do you cover? I don't claim to follow a huge number of companies (only ~15 with varying degrees of detail, though my coverage universe is gradually expanding and I am always open to new suggestions), but I do strive to deliver the most complete and in-depth due diligence research possible. Select a stock from the "Stocks" drop-down menu above or access more information and links to the individual stock research pages by clicking on "Stocks." Who operates BiotechDueDiligence? Andrew Goodwin holds a Ph.D. in the cellular and molecular basis of human disease, with a focus on infectious diseases and cancer. Find out more and connect with the author on LinkedIn, sending an email, or filling out the Contact form below. Want to be notified of all new updates to the site? Sign up for the email newsletter! |
 |
|
Feedback encouraged!
Comments? Questions? Agree? Disagree? Info I missed? Stock I should follow? Email: BiotechDueDiligence (at) gmail (dot) com Or, send a note using this form. |
|
Company Research Page Links
Adolor $ADLR - Amarin $AMRN - Antares $AIS - Alnylam $ALNY - Astex $ASTX - BioSante $BPAX - Infinity $INFI - Isis $ISIS - Ligand $LGND - Myrexis $MYRX - Momenta $MNTA - OncoGenex $OGXI - Optimer $OPTR - Senomyx $SNMX -
Synta $SNTA - Spectrum $SPPI Tekmira $TKMR - Trius $TSRX
Synta $SNTA - Spectrum $SPPI Tekmira $TKMR - Trius $TSRX
Important Disclaimer!
Biotech Due Diligence is an informal site to gather, evaluate, share, and discuss information about publicly-traded biotechnology companies. The information contained on this site is not a specific recommendation to buy or sell any particular investment. You must do your own research and evaluate each investment opportunity in regards to your personal situation. All information presented on the BiotechDueDiligence site is based on publicly-available resources - I may dig deep in conducting research, but there is no insider information on this site. In the interest of full disclosure, any contributors to Biotech Due Diligence will promptly update the disclosures page to reflect any ownership position in stocks described on this website. However, all information on this website is only current to the best of our knowledge as of the date indicated and may not reflect accurately recent events. Please also read and understand the Chimera Research Group disclaimer.
Biotech Due Diligence is an informal site to gather, evaluate, share, and discuss information about publicly-traded biotechnology companies. The information contained on this site is not a specific recommendation to buy or sell any particular investment. You must do your own research and evaluate each investment opportunity in regards to your personal situation. All information presented on the BiotechDueDiligence site is based on publicly-available resources - I may dig deep in conducting research, but there is no insider information on this site. In the interest of full disclosure, any contributors to Biotech Due Diligence will promptly update the disclosures page to reflect any ownership position in stocks described on this website. However, all information on this website is only current to the best of our knowledge as of the date indicated and may not reflect accurately recent events. Please also read and understand the Chimera Research Group disclaimer.
